Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects liver cancer drug for second time

  • 1 Comment

The liver cancer drug Nexavar (sorafenib) has been rejected for the second time by NICE

After the drug was turned down by for NHS use in May, Bayer then proposed a patient-access scheme that would have reduced its cost to the health service.

This has now been rejected by NICE, which had earlier refused it for use on the NHS for the treatment of kidney cancer.

The latest setback for Bayer and partner Onyx Pharmaceuticals has been described by the company as a “blow for patients” suffering from hepatocellular carcinoma, which accounts for 80% of all primary liver tumours.

Nexavar has proved successful against liver and kidney cancers and has been trialled for use against lung and breast tumours.

  • 1 Comment

Readers' comments (1)

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.